With these signals of safety and possible benefit for PAD-related outcomes, GLP-1 RAs could potentially be adopted as the preferred therapy over other anti-diabetic medications in patients with concurrent T2DM and PAD [77]. This evidence concerns the gene GLP1R and peripheral arterial disease.